Pernix Therapeutics (PTX) Stock Price, News & Analysis

Company Overview

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.03 to $0.21
• 52-Week Range: N/A
• Volume: 16,105 shs
• Average Volume: 3.04 million shs
• Market Capitalization: $419,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Pernix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Amira Nature Foods (ANFI) and Argos Therapeutics (ARGSQ).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PTX
• CIK: 1024126
• Web: www.pernixtx.com
• Phone: 800-793-2145
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.14 million
• Net Margins: -59.70%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -37.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.08
• Quick Ratio: 0.92

Sales & Book Value

• Annual Sales: $146.07 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($14.77) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,510,000
• Free Float: N/A
• Market Cap: $419,000.00
• Optionable: Optionable
• Beta: 1.20